Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas

详细信息

下载全文

推荐本文 |

• 作者：Manmeet S. Ahluwalia (12)
  Carol Patton (1)
  Glen Stevens (1)
  Tanya Tekautz (1)
  Lilyana Angelov (1)
  Michael A. Vogelbaum (1)
  Robert J. Weil (1)
  Sam Chao (1)
  Paul Elson (4)
  John H. Suh (13)
  Gene H. Barnett (1)
  David M. Peereboom (12) peerebd@ccf.org
• 关键词：Glioblastoma multiforme &#8211 ; HIV protease inhibitors &#8211 ; Matrix metalloproteases &#8211 ; Ritonavir/lopinavir &#8211 ; Efficacy &#8211 ; Phase II
• 刊名：Journal of Neuro-Oncology
• 出版时间：April 2011
• 出版年：2011
• 期刊代码：45_0167594X
• 类别：ch
• 卷：102
• 期：2
• 页码：317-321
• 数据来源：sp

摘要

Current therapies for recurrent or progressive high-grade gliomas (HGG, WHO grade 3–4) produce a 6-month progression-free survival of only 10–25%. Migration and invasion by HGG is mediated in part by matrix metalloproteases (MMPs) which promote remodeling of the extracellular matrix. Several HIV protease inhibitors (HIVPI) decrease the expression of MMPs in astrocytes and microglia. Given these mechanisms of antitumor activity of HIVPI, we evaluated the efficacy of ritonavir/lopinavir, a combination HIVPI, in patients with progressive or recurrent HGG in an open label phase II trial. Nineteen patients were treated in this study. Patients received ritonavir/lopinavir (400 mg/100 mg) orally twice daily. All patients were treated until progression of disease or unacceptable toxicity. A complete response was seen in one patient (5%). Three patients (16%) had stable disease as the best response. Fifteen patients (79%) had progressive disease. The 6-month progression free survival (PFS₆) was 11%(2 of 19 patients). Ritonavir/lopinavir was well tolerated in patients with heavily pretreated refractory HGG, and no grade 3 or 4 toxicity was seen. The activity at the dose and schedule used in this study, however, was modest and the study did not meet its efficacy endpoint.